Canaccord Genuity Maintains Buy on Niagen Bioscience, Raises Price Target to $16

Benzinga · 06/10 12:18
Canaccord Genuity analyst Susan Anderson maintains Niagen Bioscience (NASDAQ:NAGE) with a Buy and raises the price target from $13 to $16.